Upstream Bio, Inc. announces presentation at J.P. Morgan Healthcare Conference, focusing on treatments for inflammatory respiratory diseases.
Quiver AI Summary
Upstream Bio, Inc., a clinical-stage biotechnology company focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders, announced that CEO Rand Sutherland, MD, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The presentation will be available via a live webcast on the company's website, with a replay accessible afterward. Upstream Bio is advancing its drug, verekitug, a monoclonal antibody that targets the thymic stromal lymphopoietin (TSLP) receptor, into Phase 2 trials for conditions like chronic rhinosinusitis with nasal polyps, severe asthma, and chronic obstructive pulmonary disease. The company aims to address significant unmet medical needs in these areas.
Potential Positives
- Upstream Bio's presentation at the prestigious J.P. Morgan Healthcare Conference highlights the company's visibility and standing within the biotech community.
- The development of verekitug, a unique monoclonal antibody targeting TSLP, positions Upstream Bio in the forefront of innovative therapies for severe respiratory disorders, addressing significant unmet medical needs.
- The advancement of verekitug into Phase 2 trials for multiple serious conditions demonstrates the company's commitment to progressing its promising drug candidates.
Potential Negatives
- None
FAQ
What is Upstream Bio's focus area for treatment development?
Upstream Bio is focused on developing treatments for inflammatory diseases, primarily severe respiratory disorders.
When will Rand Sutherland present at the J.P. Morgan Healthcare Conference?
Rand Sutherland will present on January 12, 2026, at 2:15 p.m. PT.
How can I watch Upstream Bio's presentation live?
A live webcast of the presentation will be available on Upstream Bio’s website under the Events tab.
What is verekitug?
Verekitug is a monoclonal antibody in clinical development that targets the receptor for TSLP, aimed at treating immune-mediated diseases.
Where can I find more information about Upstream Bio?
More information about Upstream Bio can be found on their official website at www.upstreambio.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$UPB Hedge Fund Activity
We have seen 57 institutional investors add shares of $UPB stock to their portfolio, and 29 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ALTSHULER SHAHAM LTD removed 1,977,619 shares (-58.3%) from their portfolio in Q3 2025, for an estimated $37,199,013
- DEEP TRACK CAPITAL, LP removed 1,442,767 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $27,138,447
- VR ADVISER, LLC removed 1,126,021 shares (-49.1%) from their portfolio in Q3 2025, for an estimated $21,180,455
- TCG CROSSOVER MANAGEMENT, LLC removed 684,660 shares (-24.4%) from their portfolio in Q3 2025, for an estimated $12,878,454
- OMEGA FUND MANAGEMENT, LLC removed 680,000 shares (-33.4%) from their portfolio in Q3 2025, for an estimated $12,790,800
- STATE STREET CORP added 633,206 shares (+131.5%) to their portfolio in Q3 2025, for an estimated $11,910,604
- MARSHALL WACE, LLP added 577,473 shares (+198.8%) to their portfolio in Q3 2025, for an estimated $10,862,267
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$UPB Analyst Ratings
Wall Street analysts have issued reports on $UPB in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Mizuho issued a "Outperform" rating on 12/18/2025
- Evercore ISI Group issued a "Outperform" rating on 11/18/2025
- Truist Securities issued a "Buy" rating on 10/14/2025
To track analyst ratings and price targets for $UPB, check out Quiver Quantitative's $UPB forecast page.
$UPB Price Targets
Multiple analysts have issued price targets for $UPB recently. We have seen 4 analysts offer price targets for $UPB in the last 6 months, with a median target of $45.0.
Here are some recent targets:
- Joseph Catanzaro from Mizuho set a target price of $51.0 on 12/18/2025
- An analyst from LifeSci Capital set a target price of $43.0 on 12/02/2025
- Cory Kasimov from Evercore ISI Group set a target price of $40.0 on 11/18/2025
- Danielle Brill from Truist Securities set a target price of $47.0 on 10/14/2025
Full Release
WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will be presenting at the 44 th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 2:15 p.m. PT.
A live webcast of the presentation will be available under the Events tab on the Investors section of Upstream Bio’s website on the day of the event. A replay will be available on the Company's website following the presentation.
About Upstream Bio
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. Upstream Bio is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. Upstream Bio has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma and chronic obstructive pulmonary disease (COPD). Upstream Bio’s team is committed to maximizing verekitug’s unique attributes to address the substantial unmet needs for patients underserved by today’s standard of care. To learn more, please visit
www.upstreambio.com
.
Investor and Media Contact:
Meggan Buckwell
Director, Corporate Communications and Investor Relations
[email protected]
